Skip to main content
Wolfson Institute of Population Health
  1. WIPH
  2. People
  3. Profiles

Caitlin Fierheller, PhD

Caitlin

Postdoctoral Research Fellow in Women’s Precision Prevention

Email: c.fierheller@qmul.ac.uk

Profile

I joined the Women’s Precision Prevention (WPP) team with Prof Ranjit Manchanda as a postdoctoral research associate in February 2023. I am currently working across clinical trials in the WPP team which focus on population-based genetic testing, targeted screening, cancer prevention (including surgical) and health economics. I am a co-investigator on the PROTECT-C (Population based germline testing for early detection and prevention of cancer) and DETECT-2 (Direct to patient testing at cancer diagnosis for precision prevention-2). I also work on the Jewish Hereditary Cancer Review, PRESCORES (Preventing Endometrial Cancers: Comparing Risk-Reducing Strategies), PROTECTOR (Prevention ovarian cancer through early excision of tubes and late ovarian removal), and other studies.

I completed my PhD in Human Genetics at McGill University, Montreal, Canada in 2023. My research focused on the molecular genetics of germline potentially pathogenic variants in DNA repair pathway genes in familial ovarian cancer. I obtained my BSc in 2016 in Genetics and Biochemistry from Western University, London, Canada.

Research

Research Interests:

Cancer prevention

Cancer genetics

Population-based genetic testing

Publications

  • Zhao J, Fierheller CT, Abdy J et al. (publicationYear). Psychological, social, and ethical implications of population-based genetic testing among adults: a systematic scoping review protocol with a focus on cancer. nameOfConference


  • Fierheller CT, Deshmukh P, Kalra A et al. (2026). Direct to Patient Testing at Cancer Diagnosis for Precision Prevention-2 (DETECT-2): protocol for a two-arm equivalence UK multi-centre randomised controlled trial evaluating uptake of genetic testing. nameOfConference


  • Oxley S, Dibden A, Whenham T et al. (2026). Health-related quality of life after risk-reducing hysterectomy: a randomised vignette study. nameOfConference


  • Oxley SG, Lake M, Dibden A et al. (2026). Health-related quality of life after risk-reducing hysterectomy (PRESCORES): a cross-sectional study. nameOfConference


  • Torr B, Mansour L, Fierheller CT et al. (2026). Routine germline genetic testing in 3552 unselected NHS breast cancer patients: evidence informing testing criteria and implementation of a ‘BRCA-DIRECT’ mainstreaming pathway. nameOfConference


  • Turnbull CA, Kemp Z, Torr B et al. (2026). 7P The North thames genomics laboratory hub mainstreaming of breast cancer genetic testing programme: Outcomes from testing 3552 unselected breast cancer patients via the ‘BRCA-DIRECT’ pathway. nameOfConference


    QMRO: qmroHref
  • Ganesan S, Mansour L, Dibden A et al. (2026). Risk of ovarian cancer in women with a pathogenic or likely pathogenic variant in NBN: a systematic review and meta-analysis. nameOfConference


  • Sia J, Lane E, Fierheller C et al. (2026). Estimands for clinical effectiveness of risk reducing early salpingectomy in high risk women from prospective observational studies. nameOfConference


  • Sia J, Dibden A, Oxley S et al. (2026). Evaluating the clinical effectiveness and potential impact of opportunistic bilateral salpingectomy in 21.8 million UK general population women. nameOfConference


  • Fierheller CT, Deshmukh P, Kalra A et al. (2026). Protocol for the DETECT-2 randomised controlled trial: a comparison of direct-to-patient versus mainstreaming genetic testing at ovarian, endometrial and colorectal cancer diagnosis. nameOfConference


View profile publication page
Back to top